IXCHIQ

Approved Restricted Or Suspended

Developer: Valneva Austria GmbH  |  Target Disease: Chikungunya

Approved, with the licence restricted or suspended.

Development Phase Approved Restricted Or Suspended Primary Status
Platform Technology See FDA product page / label Biologic Architecture
Target Indication Chikungunya Pathogen / Antigen
Last Verified 2026-10-31 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Approved Restricted Or Suspended Date: 2023-11-09FDA approval / licensure action (public FDA materials)
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Regulator-confirmed status date in at least one jurisdiction.

0% of the ladderA · regulator-dated
  1. Preclinical
  2. Phase 1
  3. Phase 1/2
  4. Phase 2
  5. Phase 2/3
  6. Phase 3
  7. Submitted to a regulator
  8. Under regulatory review
  9. Approved / authorised
  10. Recommended for routine use

Stopped at unknown stage

Approved, restricted or suspended. No adoption window is projected for a stopped programme.

Scientific Profile & Documentation

Platform Architecture
See FDA product page / label
Lead Developer
Valneva Austria GmbH
Next Expected Milestone
US-licensed — see product label / ACIP for use; further supplements may expand indication
Analyst & Development Notes
FDA CBER licensed / approved vaccine (regulator-confirmed US listing). First chikungunya vaccine licensed in US; later subject to post-approval safety actions — verify current FDA status. May also have later supplements (strain updates, age expansions); see product page. Check live FDA communications for current license status (post-approval actions possible).
Primary Source Documentation
FDA — IXCHIQ →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.

Milestone Overview

  • Stage Verification
    Approved Restricted Or Suspended confirmed as of 2026-10-31.
  • Target Milestone
    US-licensed — see product label / ACIP for use; further supplements may expand indication

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.